Pentadeca Arginate
Pentadeca Arginate (PDA, pentadecapeptide arginate)
Also known as: PDA, Pentadecapeptide arginate, BPC-157 arginate
The same 15 amino acid sequence as BPC-157 with an arginine salt instead of acetate, created as a compounding workaround; it has no studies of its own and inherits BPC-157's animal-only evidence.
Overview
Pentadeca arginate appeared after the FDA placed BPC-157 in Category 2 of the compounding bulk list in 2023. Its peptide sequence (GEPPPGKPADDAGLV) is identical to BPC-157; only the counterion differs. Marketing claims it is more stable and legally distinct. Neither claim has been published or accepted by the FDA. A 2025 systematic review found the entire human evidence base for the parent peptide is one uncontrolled 12-patient case series. The parent peptide was removed from Category 2 in April 2026 and an advisory committee voted for it in July 2026, which has made the 'legal alternative' pitch moot.
Mechanism of action
Presumed identical to BPC-157: FAK-paxillin, VEGFR2 and nitric-oxide signaling supporting angiogenesis and tissue repair in animal models.
Key studies & citations
- Review2025
BPC-157 in orthopedic and sports medicine: a systematic review
Only one uncontrolled 12-patient case series exists in humans.
HSS Journal - Review2025
Safety profile of BPC-157: a review
Animal safety data; no controlled human safety data.
Pharmaceuticals - Animal2020
Toxicological evaluation of BPC-157 in multiple species
No significant toxicity in rodents and dogs at tested doses.
Regulatory Toxicology and Pharmacology
Frequently asked questions
Is pentadeca arginate different from BPC-157?
Chemically it is the same peptide with a different salt. No study shows different absorption, stability or effect.
Is it legal where BPC-157 is not?
That claim has never been validated by the FDA. Both are unapproved drugs when sold for human use.